(Untitle)● SK chemicals, leading global clinical trials for new drug
development
It turns out that SK chemicals(CEO, Chang-Geun Kim) is currently conducting the most number of international clinical trials among domestic pharmaceutical companies.
SK, supporting 7 international clinical studies, was ranked first in the number of global trials, followed by several highly-ranked domestic pharmaceutical businesses including Greencross(5 studies), Dong-A Pharm. Co.(4 studies), and Hanmi Pharm. Co.(3 studies), which are actively involved in international clinical development. (Source: Hana Daetoo Securities Co., LTD.)
Currently, SK chemicals is conducting a total of 16 clinical studies including 4 in phase III, 3 in phase II, and 9 in phase I, holding the second place in terms of the total number of ongoing clinical trials among domestic pharmas. Of the 16 studies, 7 trials are being developed in an international setting.
Dong-A Pharm. Co.,which currently sponsors 18 clinical researches, placed first with the biggest number of ongoing clinical studies among domestic pharmaceutical companies.
The number of new drug candidates in the clinical development phase is considered as an index indicating the company’s R&D power and also reflects its confidence in new drug development. Furthermore, it is widely accepted that the candidates undergoing clinical trials are validated with their potentials for commercialization.
Bong-yong Lee(Director, SK chemicals’ Life Science Research Center) noted, “Our accomplishment is the fruit of continued investment in R&D with more than 10% of our sales since 2000. The biggest strength of SK chemicals is in its extensive portfolio for new drug development including small molecules, biologicals and natural products.
While many pharmaceutical companies are going through tough times due to a series of changes in governmental policy, SK chemicals, which has already experienced 3 successful cases of new drug commercialization on its own merits, will overcome any challenges with commitment to new drug development as our strongest asset.
? Appendix :<Table> Status of clinical development by major domestic pharmaceutical companies
? Status of clinical development by major domestic pharmaceutical companies
Company Name | Number of ongoing clinical studies(including international studies) | Number of ongoing international clinical studies |
Hanmi Pharm. Co. | 7 | 3 |
LG Life Sciences | 6 | 3 |
Daewoong Pharm. Co. | 6 | |
Chong Kun Dang Pharm. Co., Jw Pharmaceutical Co., Yuhan Co.,
Dong Wha Pharm. Co.,
Bukwang Pharm. Co. 3,
respectively - | 3, respectively | |